SCL delivered a strong 2Q26 rebound, with net sales increasing 15% year-over-year to $684.1M and adjusted EBITDA rising 45% to $74.4M, driven by a recovery in the Surfactants segment, organic volume growth, pricing improvements, and ongoing Project Catalyst cost savings. While results exceeded expectations, management cautioned that 2Q should not be viewed as a sustainable quarterly run rate, noting that customer pre-buying likely pulled forward $5M-$10M of EBITDA from 3Q and that a planned Polymer turnaround will create a $4M-$5M headwind in the second half. Despite these near-term factors, the Company maintained its outlook for full-year adjusted EBITDA growth, positive free cash flow, continued deleveraging, and expanding operational savings, while Stonegate reiterated its long-term positive view supported by market share gains, manufacturing efficiencies, and a 2027 price target of $75.25.